{"schema_version":"secwatch.filing_event.v1","accession":"0001447028-25-000093","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.321776+00:00","generated_at":"2026-05-23T22:26:41.955528+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arbutus Biopharma finalizes separation agreements with ex-CMO and ex-CFO; updates Moderna trial date","bullets":["CMO Karen Sims terminated without cause effective March 25, 2025; enters 30-day consulting agreement with hourly fee and extended option exercise to March 24, 2026.","CFO David Hastings terminated without cause effective March 27, 2025; separation agreement extends option exercise to March 26, 2026.","Patent litigation vs Moderna: District of Delaware moved trial start from September 24 to September 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001447028-25-000093","json":"https://secwatch.observer/filing/0001447028-25-000093.json","markdown":"https://secwatch.observer/filing/0001447028-25-000093.md","text":"https://secwatch.observer/filing/0001447028-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/abus-20250328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:26:41.955528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72014df024","claim":"Karen Sims departed as Chief Medical Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"93289701b1","claim":"David Hastings departed as Chief Financial Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}